Table 2.

The dose of human HBV (MS2 strain) and human HCV (Hutchinson strain) treated with PCT and order of transfusion in the two phases of the study *

Phase	Chimp X283	Chimp X286	Chimp X317
I	103.5 CID50 † HBV	104.5 CID50 HCV	105.5 CID50 HBV
II	104.5 CID50 HCV	104.5 CID50 HBV	104.5 CID50 HCV

^* In each phase of the study, after transfusion with treated PLT concentrates, the animals were followed for a 6‐month period for development of serologic, biochemical, molecular, and clinical signs of viral infection or disease.

^† The infectivity of HBV and HCV is expressed in chimpanzee infectious dose (CID₅₀).